Cure My Disease

Don't miss your cure!

 Log in / Sign up

Global study tracks Real-World impact of new heart drug

NCT ID NCT07358078

Recruiting now Knowledge-focused Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow about 2000 adults with a heart condition called ATTR-CM, where abnormal proteins build up and weaken the heart. Researchers want to see how patients do on a drug called vutrisiran in everyday medical care, not just in a controlled trial. They will measure symptoms, quality of life, and how often patients need hospital care over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Trial Site

    RECRUITING

    Naples, Florida, 34102, United States

  • Clinical Trial Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Clinical Trial Site

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Clinical Trial Site

    RECRUITING

    Memphis, Tennessee, 38120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.